Jasper Therapeutics Inc.
Jasper Therapeutics Inc. (JSPR): 2 pipeline candidates · 2 upcoming catalysts · ~3 mo cash runway · 16 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
3.4 months
D/E 5.23 · 2% dilution
Lead: Phase 2
2 candidates
2 upcoming, next in ~1108d
N/A
A transparent, data-derived signal for Jasper Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$13.5M
Cash
$14.6M
Quarterly Burn
$14.5M
Runway
3.4 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| briquilimab | Phase 2 |
| humanized anti-cd117 monoclonal antibody | Phase 1/Phase 2 |
Upcoming Catalysts (2)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
56
Total value held
$11.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,345,194 | $2.1M |
| millennium management llc | 1,617,531 | $1.4M |
| acorn capital advisors, llc | 1,411,492 | $1.2M |
| kingdon capital management, l.l.c. | 1,352,106 | $1.2M |
| morgan stanley | 1,333,420 | $1.2M |
| rock springs capital management lp | 1,100,726 | $964K |
| boothbay fund management, llc | 582,751 | $511K |
| jacobs levy equity management, inc | 322,273 | $282K |
| geode capital management, llc | 317,677 | $278K |
| bank of america corp /de/ | 293,259 | $257K |
Showing top 10 of 56 institutional holders of Jasper Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Jasper Therapeutics Inc.'s pipeline?
Jasper Therapeutics Inc. (JSPR) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Jasper Therapeutics Inc.'s lead drug candidate?
Jasper Therapeutics Inc.'s most advanced tracked candidate is briquilimab (Phase 2) for Chronic Inducible Urticaria; Chronic Spontaneous Urticaria; Urticaria Chronic.
What is Jasper Therapeutics Inc.'s next catalyst?
Jasper Therapeutics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Efficacy and Implementation of Exercise-based Smoking Cessation Treatment for Adults With High Anxie" — expected June 30, 2029.
What is Jasper Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Jasper Therapeutics Inc. has approximately 3.4 months of cash runway.
What is Jasper Therapeutics Inc.'s market capitalization?
Jasper Therapeutics Inc.'s market capitalization is approximately $13.5M.
Get the full picture on Jasper Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.